Ruxolitinib Cream (Opzelura) US version price and international market reference information

Ruxolitinib cream (Opzelura, scientific name is ruxolitinib ointment) is a JAK inhibitor topical preparation, mainly used for the treatment of diseases such as vitiligo and atopic dermatitis. Since the drug has not yet been approved for marketing in China, patients can only purchase it through overseas channels if they need it. As the main market for the original drug, the price of ruxolitinib cream in the United States is very expensive. One tube often costs more than 10,000 yuan, which puts great financial pressure on ordinary families and limits the accessibility for some patients.

In the international market, in addition to the original version in the United States, the prices in some countries and regions are also higher, but generally close to the level of the original version, and the purchase channels are mostly through regular pharmacies and prescriptions. In some generic drug-producing countries, such as Bangladesh, generic versions of ruxolitinib cream are already on the market. The price is about a few hundred yuan, which is dozens of times cheaper than the original drug. These generic drugs are consistent with the original drugs in terms of drug ingredients and mechanism of action, so they are generally consistent in efficacy and safety, providing an option for patients with limited economic conditions.

However, it needs to be emphasized that there are certain risks in purchasing drugs through overseas channels, including difficulties in ensuring the authenticity of drugs, non-standard transportation and storage conditions, and lack of domestic medical supervision. If patients consider using foreign original drugs or Bangladeshi generic drugs, they should try to obtain them through formal channels and use them under the guidance of a doctor to avoid adverse reactions or dosage issues caused by self-use. In addition, some international medical institutions or cross-border medical services can provide relatively reliable ways to purchase drugs, but the costs and procedures are also more complicated.

Overall, ruxolitinib cream is expensive in developed countries such as the United States, but generic drugs in countries such as Bangladesh provide patients with more economical options. While it has not yet been launched in the country, patients need to weigh the drug's accessibility, economic burden and medication safety, carefully choose purchasing channels, and pay close attention to the domestic approval progress. Once approved and listed and included in medical insurance, patients' medication burden will be greatly reduced.

Reference materials:https://www.drugs.com/